Articles

Early integration of palliative care into oncology programs improves quality of life for patients and caregivers, increases prognostic understanding, and demonstrates survival benefits while substantially reducing costs... Read More ›

Cancer-related cachexia is a debilitating condition that has had no effective treatment thus far. Its symptoms include loss of lean body mass, as well as muscle wasting and loss of appetite. Read More ›

Routine surveillance imaging of asymptomatic patients in first remission after treatment for diffuse large B-cell lymphoma offers little clinical benefit at substantial cost, according to Scott F. Huntington, MD, of Abramson Cancer Center, University of Pennsylvania, Philadelphia, and colleagues. Read More ›

There’s a lot we don’t know about lung cancer screening,” according to Denise Aberle, MD... However, certain measures can be taken to lower false-positive and overdiagnosis rates, lessen costs, ameliorate patient suffering, and correctly identify screening cohorts, she asserted. Read More ›

Read More ›

Patients who are diagnosed with lung cancer but continue to smoke are at much higher risk of developing a secondary primary lung cancer (SPLC) compared with never smokers as well as those who have quit smoking, according to the largest analysis of its kind. “This study, which looked at the relationship between smoking history and developing a second lung cancer, adds to the evidence of the harmfulness of cigarette smoking. We presumed that never smokers would have a lower risk than current smokers, but we were encouraged to find that quitting smoking lowered the risk of SPLC and quitters had similar overall survival rates as never smokers,” said John Michael Boyle, MD, lead author, a radiation oncology resident at Duke Cancer Institute in Durham, North Carolina. Read More ›

Evidence-based healthcare, considered to be the best healthcare in the world, is a premise that many believe has become the norm in the United States. However, there are several reasons why this is not always the case. For example, one traditional standard is the empirical approach of teaching in the medical profession, “see one, do one, teach one,” which is not necessarily based on current best evidence. This method may have been the best available in the past, but as research and medicine are moving more quickly than ever before, healthcare providers need additional tools to keep abreast of advances founded on evidence-based research. Read More ›

In patients receiving everolimus in clinical trials, stomatitis frequently occurred in the initial weeks of treatment, but this did not compromise clinical outcomes, according to Hope S. Rugo, MD, Professor of Medicine and Director of Breast Oncology and Clinical Trials at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. Read More ›

For a cancer survivor, it’s enough to lay you flat. There’s a day when you learn that someone who has been in your survivor universe is no longer a part of that universe. And this news not only shakes you to the core, it roils the pot of emotions resting on your internal stovetop to a vigorous boil. Read More ›

The first multigene panels for colorectal cancer became clinically available in 2012. Prior to that date, clinical testing for inherited colorectal cancer syndromes typically proceeded in a sequential fashion. A clinician would develop a differential diagnosis and test corresponding genes in order of those most likely to have a causative mutation. Thus, analyzing multiple genes for inherited colorectal cancer risk was both time intensive and costly. Read More ›